Literature DB >> 24323476

In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.

James A Karlowsky1, Andrew J Denisuik, Philippe R S Lagacé-Wiens, Heather J Adam, Melanie R Baxter, Daryl J Hoban, George G Zhanel.   

Abstract

We tested 868 urinary isolates of Escherichia coli collected from 2010 to 2013 as part of the Canadian national surveillance study CANWARD against fosfomycin by using the Clinical and Laboratory Standards Institute (CLSI) agar dilution method with MIC interpretation in accordance with the CLSI M100-S23 (2013) criteria. The concentrations of fosfomycin inhibiting 50 and 90% of the isolates were ≤1 and 4 μg/ml; 99.4% of the isolates were susceptible to fosfomycin.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24323476      PMCID： PMC3910835          DOI： 10.1128/AAC.02399-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

2.  Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

Authors:  Simon Auer; Alexandra Wojna; Markus Hell
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

3.  Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study.

Authors:  James A Karlowsky; Philippe R S Lagacé-Wiens; Patricia J Simner; Melanie R DeCorby; Heather J Adam; Andrew Walkty; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

4.  Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.

Authors:  Jesús Oteo; Verónica Bautista; Noelia Lara; Oscar Cuevas; Margarita Arroyo; Sara Fernández; Edurne Lázaro; Francisco J de Abajo; José Campos
Journal:  J Antimicrob Chemother       Date:  2010-09-16       Impact factor: 5.790

5.  In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010.

Authors:  Guillermo V Sanchez; Ronald N Master; James A Karlowsky; Jose M Bordon
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

Review 6.  Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.

Authors:  Drosos E Karageorgopoulos; Rui Wang; Xu-Hong Yu; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2011-11-16       Impact factor: 5.790

7.  Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.

Authors:  Hsin-Yi Liu; Hsiu-Chen Lin; Yi-Chun Lin; Shao-Hua Yu; Wui-Hsiu Wu; Yuarn-Jang Lee
Journal:  J Microbiol Immunol Infect       Date:  2011-01-20       Impact factor: 4.399

8.  Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.

Authors:  Andrew J Denisuik; Philippe R S Lagacé-Wiens; Johann D Pitout; Michael R Mulvey; Patricia J Simner; Franil Tailor; James A Karlowsky; Daryl J Hoban; Heather J Adam; George G Zhanel
Journal:  J Antimicrob Chemother       Date:  2013-05       Impact factor: 5.790

9.  Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.

Authors:  Elizabeth A Neuner; Jennifer Sekeres; Gerri S Hall; David van Duin
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

10.  Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates.

Authors:  Pak-Leung Ho; Jane Chan; Wai-U Lo; Eileen L Lai; Yuk-Yam Cheung; Terrence C K Lau; Kin-Hung Chow
Journal:  J Med Microbiol       Date:  2013-08-29       Impact factor: 2.472
View more
  20 in total

1.  Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.

Authors:  Vrushali Patwardhan; Sarman Singh
Journal:  Int Urol Nephrol       Date:  2017-06-14       Impact factor: 2.370

Review 2.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

Review 3.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

4.  Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.

Authors:  Sangeeta Sastry; Lloyd G Clarke; Hind Alrowais; Ashley M Querry; Kathleen A Shutt; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

5.  Glutathione-S-transferase FosA6 of Klebsiella pneumoniae origin conferring fosfomycin resistance in ESBL-producing Escherichia coli.

Authors:  Qinglan Guo; Adam D Tomich; Christi L McElheny; Vaughn S Cooper; Nicole Stoesser; Minggui Wang; Nicolas Sluis-Cremer; Yohei Doi
Journal:  J Antimicrob Chemother       Date:  2016-06-03       Impact factor: 5.790

6.  Fosfomycin: An Alternative Therapy for the Treatment of UTI Amidst Escalating Antimicrobial Resistance.

Authors:  Ekadashi Rajni Sabharwal; Rajni Sharma
Journal:  J Clin Diagn Res       Date:  2015-12-01

7.  F33: A-: B-, IncHI2/ST3, and IncI1/ST71 plasmids drive the dissemination of fosA3 and bla CTX-M-55/-14/-65 in Escherichia coli from chickens in China.

Authors:  Xiaoyun Yang; Wuling Liu; Yiyun Liu; Jing Wang; Luchao Lv; Xiaojie Chen; Dandan He; Tong Yang; Jianxia Hou; Yinjuan Tan; Li Xing; Zhenling Zeng; Jian-Hua Liu
Journal:  Front Microbiol       Date:  2014-12-16       Impact factor: 5.640

Review 8.  Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis.

Authors:  George G Zhanel; Andrew J Walkty; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-05-10       Impact factor: 2.471

9.  Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012.

Authors:  Tiffany R Keepers; Marcela Gomez; Chris Celeri; Kevin M Krause; Donald Biek; Ian Critchley
Journal:  Infect Dis Ther       Date:  2017-03-11

10.  Fosfomycin Susceptibility in Multidrug-Resistant Enterobacteriaceae Species and Vancomycin-Resistant Enterococci Urinary Isolates.

Authors:  Linda B Ou; Lynn Nadeau
Journal:  Can J Hosp Pharm       Date:  2017-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.